1
|
Ao K, Yin M, Lyu X, Xiao Y, Chen X, Zhong S, Wen X, Yuan J, Ye M, Zhang J, Li X, Hao Y, Guo X. METTL3-mediated HSPA9 m6A modification promotes malignant transformation and inhibits cellular senescence by regulating exosomal mortalin protein in cervical cancer. Cancer Lett 2024; 587:216658. [PMID: 38253218 DOI: 10.1016/j.canlet.2024.216658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Revised: 01/16/2024] [Accepted: 01/16/2024] [Indexed: 01/24/2024]
Abstract
The role of RNA methyltransferase 3 (METTL3) in tumor progression when tethered to aberrantly expressed oncogenes remains unknown. In especial, the correlation between cervical cancer (CCa)-derived exosomes and m6A methylation in malignant traits of cervical epithelium is currently elusive. Mortalin expression was found to be up-regulated in plasma exosomes isolated from CCa patients. Furthermore, mortalin gained increased mRNA stability and enhanced translation efficiency via the m6A methylation in the HSPA9 mRNA 3'UTR, which was catalysed by METTL3 in CCa cells. Exosomal mortalin overexpression significantly promoted the proliferation, migration and invasion of CCa both in vitro and in vivo. Additionally, exosome-encapsulated mortalin suppressed cellular senescence and facilitated malignant transformation by blocking nuclear transport of p53, thereby preventing the p53-Gadd45A interaction and resulting in inactivation of p53. Our studies demonstrated the significant role of METTL3 mediated exosomal mortalin in malignant transformation and cellular senescence suppression of CCa. Exosomal mortalin could clinically serve as a potential early-diagnosis biomarker and therapeutic target for CCa given its abundance and propensity to be found.
Collapse
Affiliation(s)
- Keyi Ao
- Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, 518100, PR China; The Third School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, PR China.
| | - Minuo Yin
- Department of Obstetrics and Gynecology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, 518100, PR China.
| | - Xiaoming Lyu
- Department of Laboratory Medicine, The Third Affiliated Hospital, Southern Medical University, Guangdong, 510515, PR China.
| | - Yue Xiao
- Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, 518100, PR China; The Third School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, PR China.
| | - Xiaona Chen
- Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, 518100, PR China; The Third School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, PR China.
| | - Sheng Zhong
- Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, 518100, PR China; The Third School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, PR China.
| | - Xiuli Wen
- Department of Ultrasound, South China Hospital of Shenzhen University, Shenzhen, Guangdong, 518100, PR China.
| | - Jianli Yuan
- Department of Gynecology, Affiliated Cancer Hospital, Xinjiang Medical University, Urumqi, Xiangjiang, 830000, PR China.
| | - Ming Ye
- Department of Pathology, Afiliated Cancer Hospital, Xinjiang Medical University, Urumqi, Xiangjiang, 830000, PR China.
| | - Jiaming Zhang
- Department of Obstetrics and Gynecology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, 518100, PR China.
| | - Xin Li
- Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, 518100, PR China; The Third School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, PR China; Shenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, 518100, PR China.
| | - Yi Hao
- Department of Ultrasound, South China Hospital of Shenzhen University, Shenzhen, Guangdong, 518100, PR China.
| | - Xia Guo
- Department of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, 518100, PR China; The Third School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, PR China; Shenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, 518100, PR China.
| |
Collapse
|
2
|
Rojpibulstit P, Kittisenachai S, Puthong S, Manochantr S, Gamnarai P, Jitrapakdee S, Roytrakul S. Hep88 mAb-initiated paraptosis-like PCD pathway in hepatocellular carcinoma cell line through the binding of mortalin (HSPA9) and alpha-enolase. Cancer Cell Int 2014; 14:69. [PMID: 25788858 PMCID: PMC4364037 DOI: 10.1186/s12935-014-0069-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2014] [Accepted: 07/08/2014] [Indexed: 12/31/2022] Open
Abstract
Background Hepatocellular carcinoma (HCC) is the most prevalent hepatic cancer worldwide. Currently, a targeted therapy via monoclonal antibodies (mAbs) specific to tumor-associated antigen is undergoing continual development in HCC treatment. Methods In this regard, after establishing and consequently exploring Hep88 mAb’s tumoricidal effect on hepatocellular carcinoma cell line (HepG2 cell line), the Hep88 mAb’s specific antigens from both membrane and cytoplasmic fractions of HepG2 cell line were identified by 2-D gel electrophoresis and western blot analysis. After in-gel digestion and subsequent analysis by liquid chromatography-mass spectrometry (LC-MS), mortalin (HSPA9) and alpha-enolase were identified. The recombinant proteins specific to Hep88 mAb were cloned and expressed in E. coli BL21(DE3). Moreover, alteration of HepG2 and Chang liver cell line after being induced by Hep88 mAb for 1–3 days was investigated using a transmission electron microscope. Results The result demonstrated that Hep88 mAb can bind to the recombinant mortalin (HSPA9) and alpha-enolase. In addition, the gradual appearing of mitochondria vacuolization and endoplasmic reticulum dilatation were observed. Those characteristics might be explained by the paraptosis-like program cell death (PCD), which is induced by the binding of Hep88 mAb to mortalin (HSPA9). Mortalin depletion resulting from the formation of Hep88 mAb-mortalin (HSPA9) complex might initiate transcription-independence of p53-mediated apoptosis. Additionally, Hep88mAb-alpha-enolase complex might initiate HepG2 cells energy exhaustion by glycolysis pathway obstruction. Conclusion These fascinating results imply that Hep88 mAb might be a promising tool for the development of an effective treatment of HCC in the next decade.
Collapse
Affiliation(s)
- Panadda Rojpibulstit
- Faculty of Medicine, Thammasat University (Rangsit Campus), Khlong Luang 12121, Pathum Thani, Thailand ; Department of Preclinical Science, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand
| | - Suthathip Kittisenachai
- Thailand National Center for Genetic Engineering and Biotechnology (BIOTEC), Thailand Science Park, Phahonyothin Road, Khlong Luang 12120, Pathum Thani, Thailand
| | - Songchan Puthong
- Antibody Production Research Unit, Institute of Biotechnology and Genetic Engineering, Chulalongkorn University, Pathum Wan 10330, Bangkok, Thailand
| | - Sirikul Manochantr
- Faculty of Medicine, Thammasat University (Rangsit Campus), Khlong Luang 12121, Pathum Thani, Thailand
| | - Pornpen Gamnarai
- Faculty of Medicine, Thammasat University (Rangsit Campus), Khlong Luang 12121, Pathum Thani, Thailand
| | - Sarawut Jitrapakdee
- Molecular Metabolism Research Group, Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
| | - Sittiruk Roytrakul
- Thailand National Center for Genetic Engineering and Biotechnology (BIOTEC), Thailand Science Park, Phahonyothin Road, Khlong Luang 12120, Pathum Thani, Thailand
| |
Collapse
|